Cancer related fatigue (CRF) is a common problem suffered by many cancer survivors, including men with advanced prostate cancer. Whether the fatigue is a result of the cancer or of the treatment doesn’t really matter. What matters is that you are fatigued and unable to live your life as you wish. CRF can affect us [...]
Johns Hopkins Kimmel Cancer Center along with Danish researchers have announced the development of a novel, investigational anticancer drug (G202) that has been described as a molecular grenade that targets cancer cells. The drug is able to travel undetected by normal cells through the bloodstream until it is activated by a specific cancer proteins, then [...]
It has just been announced that there are now two new additional sites added to the Early/Expanded Access Program for Enzalutamide (MDV3100). The program is technically a clinical trial designed to monitor MDV-3100’s safety in men with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. This means that there are now a total of [...]
At a recent meeting that I attended it was reported by a nurse that one of her patients with advanced prostate cancer with only a PSA recurrence and lymph node involvement on a scan was rejected by their insurance company for reimbursement for Provenge. The insurance company indicated that to pay for the treatment they [...]
Androgen deprivation therapy (ADT) is an old standby for the treatment of men with metastatic or advanced prostate cancer. We have long known that testosterone plays an integral role in the progression of prostate cancer, thus we often use it as an initial treatment for men who become metastatic. ADT is used both for men [...]